Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments
“While the COVID-19 pandemic has presented unexpected challenges, we continue to execute on our pipeline and business strategy, and we look forward to further progress throughout 2020,” said
Recent Developments and Highlights
February 2020, Atrecacommenced patient dosing in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. Patient screening continues in the study and, to date, three subjects have been enrolled in the first dose cohort. The ongoing COVID-19 pandemic is likely to impact our ability to initiate additional clinical trial sites quickly, which may ultimately result in enrollment delays.
Atrecaannounced a collaboration with BeiGene, Ltd. and IGM Biosciences, Inc. to discover and develop a novel antibody treatment for COVID-19. The alliance will utilize Atreca’s proprietary discovery platform to generate the sequences of antibodies made by particular B cells found in blood obtained from acutely infected COVID-19 patients.
Atrecawill present a trial-in-progress poster at the upcoming American Society of Clinical Oncology(ASCO) 2020 Virtual Scientific Program being held from May 29 to May 31, 2020. The poster will describe the design of Atreca’s ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.
First Quarter 2020 Financial Results
- As of
March 31, 2020, cash, cash equivalents and investments totaled $166.3 million.
- Research and development expenses for the three months ended
March 31, 2020were $14.2 million, including non-cash share-based compensation expense of $1.1 million.
- General and administrative expenses for the three months ended
March 31, 2020were $7.1 million, including non-cash share-based compensation expense of $1.4 million.
Atrecareported a net loss of $20.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.73, for the three months ended March 31, 2020.
This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “believe,” “likely,” “may,” “will,” “forward,” “potential,” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the
|Condensed Consolidated Balance Sheets|
|(in thousands, except share and per share data)|
|Cash and cash equivalents||$||92,183||$||157,954|
|Prepaid expenses and other current assets||3,147||3,502|
|Total current assets||154,210||176,119|
|Property and equipment, net||6,632||5,771|
|Deposits and other||2,898||3,026|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Other current liabilities||1,549||419|
|Total current liabilities||6,857||7,947|
|Capital lease obligations, net of current portion||41||53|
|Other non-current liabilities||505||-|
|Additional paid-in capital||354,477||351,039|
|Accumulated other comprehensive loss||179||16|
|Total stockholders’ equity||170,135||186,952|
|Total liabilities and stockholders’ equity||$||178,969||$||195,715|
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
|Three Months Ended|
|Research and development||$||14,210||$||11,713|
|General and administrative||7,123||2,518|
|Interest and other income (expense)|
|Preferred stock warrant liability revaluation||—||(50||)|
|Loss on disposal of property and equipment||—||(5||)|
|Loss before Income tax expense||(20,418||)||(13,578||)|
|Income tax benefit (expense)||—||(1||)|
|Net loss per share, basic and diluted||$||(0.73||)||$||(6.40||)|
|Weighted-average shares used in computing|
|net loss per share, basic and diluted||28,020,408||2,120,925|
Chief Financial Officer
Source: Atreca, Inc.